Investigational new drugs

Keyphrases

Publications

volume 42, number 3, 2024

Huifen Zhou, Xiaoxia Wu, Zhen Yang, Shenqi Lu, Xinhui Zhang, Xiaofei Yang, Suning Chen, Depei Wu, Miao Miao
Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia. Investigational new drugs 42 (3) (2024)
Xinyi Liu, Zihan Guo, Lin Su, Anli Zuo, Min Gao, Xiang Ji, Jiameng Lu, Shuran Yang, Yunxiu Jiang, Degan Lu
The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer. Investigational new drugs 42 (3) (2024)
Shannon S Stockton, G Dan Ayers, Cody Lee, Heather Laferriere, Satya Das, Jordan Berlin
Evolving or immutable - phase I solid tumor trials in the era of precision oncology. Investigational new drugs 42 (3) (2024)
Tomoki Hori, Kazuhiro Yamamoto, Takefumi Ito, Shigeki Ikushima, Tomohiro Omura, Ikuko Yano
Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer. Investigational new drugs 42 (3) (2024)
Kazuma Fujita, Daiki Taguchi, Koji Fukuda, Taichi Yoshida, Kazuhiro Shimazu, Hanae Shinozaki, Hiroyuki Shibata, Masatomo Miura
Association between albumin-bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients. Investigational new drugs 42 (3) (2024)
Noboru Yamamoto, Miyako Satouchi, Toshihiko Doi, Yutaka Fujiwara, Noriko Yanagitani, Yoshitaka Kawa, Kiyotaka Yoh, Lance Leopold, Mihaela Munteanu, Takashi Sawada, Shirong Han, Kazuo Noguchi, Makoto Nishio
KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer. Investigational new drugs 42 (3) (2024)
Xinyi Liu, Zihan Guo, Lin Su, Anli Zuo, Min Gao, Xiang Ji, Jiameng Lu, Shuran Yang, Yunxiu Jiang, Degan Lu
The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer. Investigational new drugs 42 (3) (2024)
Shannon S Stockton, G Dan Ayers, Cody Lee, Heather Laferriere, Satya Das, Jordan Berlin
Evolving or immutable - phase I solid tumor trials in the era of precision oncology. Investigational new drugs 42 (3) (2024)
Maxime Chénard-Poirier, Aaron R Hansen, Martin E Gutierrez, Drew Rasco, Yan Xing, Lin-Chi Chen, Heng Zhou, Andrea L Webber, Tomoko Freshwater, Manish R Sharma
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors. Investigational new drugs 42 (3) (2024)
Fatemeh Safari, Setareh Bararpour, Fatemeh Omidi Chomachaei
The suppression of cell motility through the reduction of FAK activity and expression of cell adhesion proteins by hAMSCs secretome in MDA-MB-231 breast cancer cells. Investigational new drugs 42 (3) (2024)
Wenjie Li, Wei Wang
Toxicity burden patterns of MET-selective tyrosine kinase inhibitors: evidence from real-world pharmacovigilance. Investigational new drugs 42 (3) (2024)
Xinyi Liu, Zihan Guo, Lin Su, Anli Zuo, Min Gao, Xiang Ji, Jiameng Lu, Shuran Yang, Yunxiu Jiang, Degan Lu
The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer. Investigational new drugs 42 (3) (2024)
Maxime Chénard-Poirier, Aaron R Hansen, Martin E Gutierrez, Drew Rasco, Yan Xing, Lin-Chi Chen, Heng Zhou, Andrea L Webber, Tomoko Freshwater, Manish R Sharma
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors. Investigational new drugs 42 (3) (2024)
Noboru Yamamoto, Miyako Satouchi, Toshihiko Doi, Yutaka Fujiwara, Noriko Yanagitani, Yoshitaka Kawa, Kiyotaka Yoh, Lance Leopold, Mihaela Munteanu, Takashi Sawada, Shirong Han, Kazuo Noguchi, Makoto Nishio
KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer. Investigational new drugs 42 (3) (2024)
Bei Cao, Tingting Ma, Yuqiang Zhang, Lei Huang, Hui Lin, Huanhuan Jiang, Yu Zhao, Yan Geng, Yuanxun Yang, Sumin Cao, Juan Li
The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects. Investigational new drugs 42 (3) (2024)
Kazuma Fujita, Daiki Taguchi, Koji Fukuda, Taichi Yoshida, Kazuhiro Shimazu, Hanae Shinozaki, Hiroyuki Shibata, Masatomo Miura
Association between albumin-bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients. Investigational new drugs 42 (3) (2024)
Maxime Chénard-Poirier, Aaron R Hansen, Martin E Gutierrez, Drew Rasco, Yan Xing, Lin-Chi Chen, Heng Zhou, Andrea L Webber, Tomoko Freshwater, Manish R Sharma
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors. Investigational new drugs 42 (3) (2024)
Kazuma Fujita, Daiki Taguchi, Koji Fukuda, Taichi Yoshida, Kazuhiro Shimazu, Hanae Shinozaki, Hiroyuki Shibata, Masatomo Miura
Association between albumin-bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients. Investigational new drugs 42 (3) (2024)
Shannon S Stockton, G Dan Ayers, Cody Lee, Heather Laferriere, Satya Das, Jordan Berlin
Evolving or immutable - phase I solid tumor trials in the era of precision oncology. Investigational new drugs 42 (3) (2024)
Noboru Yamamoto, Miyako Satouchi, Toshihiko Doi, Yutaka Fujiwara, Noriko Yanagitani, Yoshitaka Kawa, Kiyotaka Yoh, Lance Leopold, Mihaela Munteanu, Takashi Sawada, Shirong Han, Kazuo Noguchi, Makoto Nishio
KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer. Investigational new drugs 42 (3) (2024)
Maxime Chénard-Poirier, Aaron R Hansen, Martin E Gutierrez, Drew Rasco, Yan Xing, Lin-Chi Chen, Heng Zhou, Andrea L Webber, Tomoko Freshwater, Manish R Sharma
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors. Investigational new drugs 42 (3) (2024)
Xinyi Liu, Zihan Guo, Lin Su, Anli Zuo, Min Gao, Xiang Ji, Jiameng Lu, Shuran Yang, Yunxiu Jiang, Degan Lu
The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer. Investigational new drugs 42 (3) (2024)

volume 42, number 4, 2024

Randeep Sangha, Rahima Jamal, Jennifer Spratlin, John Kuruvilla, Laurie H Sehn, Erwan Beauchamp, Michael Weickert, Luc G Berthiaume, John R Mackey
A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas. Investigational new drugs 42 (4) (2024)
Michael J Hanley, Steven Zhang, Robert J Griffin, Sean Xiaochun Zhu, Robert J Fram, Jianchang Lin, Karthik Venkatakrishnan, Neeraj Gupta
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [ 14 C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Investigational new drugs 42 (4) (2024)
Panpan Luo, Yuge Guo, Yang He, Chunjiang Wang
Clinical characteristics, treatment and outcome of pembrolizumab-induced acute pancreatitis. Investigational new drugs 42 (4) (2024)
Jing Zhang, Wenwei Yang, Junbao Liu, Nan Wang, Zhaoying Ren, Tingting Yang, Gongli Xie, Guifu Wu, Yongkun Sun
Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer. Investigational new drugs 42 (4) (2024)
Noboru Yamamoto, Yasutoshi Kuboki, Kenichi Harano, Takafumi Koyama, Shunsuke Kondo, Akiko Hagiwara, Noriko Suzuki, Ei Fujikawa, Kiichiro Toyoizumi, Mayumi Mukai, Toshihiko Doi
A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors. Investigational new drugs 42 (4) (2024)
Kazufumi Kobayashi, Sadahisa Ogasawara, Ei Itobayashi, Tomomi Okubo, Norio Itokawa, Kazuyoshi Nakamura, Michihisa Moriguchi, Shunji Watanabe, Masafumi Ikeda, Hidekatsu Kuroda, Tomokazu Kawaoka, Atsushi Hiraoka, Yutaka Yasui, Teiji Kuzuya, Rui Sato, Hiroaki Kanzaki, Keisuke Koroki, Masanori Inoue, Masato Nakamura, Soichiro Kiyono, Naoya Kanogawa, Takayuki Kondo, Shingo Nakamoto, Yoshihito Ozawa, Kaoru Tsuchiya, Masanori Atsukawa, Hiroshi Aikata, Takeshi Aramaki, Shiro Oka, Naoki Morimoto, Masayuki Kurosaki, Yoshito Itoh, Namiki Izumi, Naoya Kato
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study). Investigational new drugs 42 (4) (2024)
Tomoya Yokota, Satoshi Hamauchi, Takeshi Kawakami, Kunihiro Fushiki
Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer. Investigational new drugs 42 (4) (2024)
Hongwei Liu, Qianqian Wang, Wanying Lan, Duanya Liu, Jiangang Huang, Jie Yao
Radiosensitization effect of quinoline-indole-schiff base derivative 10E on non-small cell lung cancer cells in vitro and in tumor xenografts. Investigational new drugs 42 (4) (2024)
Kazufumi Kobayashi, Sadahisa Ogasawara, Ei Itobayashi, Tomomi Okubo, Norio Itokawa, Kazuyoshi Nakamura, Michihisa Moriguchi, Shunji Watanabe, Masafumi Ikeda, Hidekatsu Kuroda, Tomokazu Kawaoka, Atsushi Hiraoka, Yutaka Yasui, Teiji Kuzuya, Rui Sato, Hiroaki Kanzaki, Keisuke Koroki, Masanori Inoue, Masato Nakamura, Soichiro Kiyono, Naoya Kanogawa, Takayuki Kondo, Shingo Nakamoto, Yoshihito Ozawa, Kaoru Tsuchiya, Masanori Atsukawa, Hiroshi Aikata, Takeshi Aramaki, Shiro Oka, Naoki Morimoto, Masayuki Kurosaki, Yoshito Itoh, Namiki Izumi, Naoya Kato
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study). Investigational new drugs 42 (4) (2024)
Sujinna Lekmeechai, Kristian Pietras, Oskar Axelsson
177 Lu-SN201 nanoparticle shows superior anti-tumor efficacy over conventional cancer drugs in 4T1 orthotopic model. Investigational new drugs 42 (4) (2024)
Jingqiao Wu, Zhaoyu Lan, Xin Li, Jinling He, Dongchao Zhang, Tianming Jin
A novel recombinant adenovirus expressing apoptin and melittin genes kills hepatocellular carcinoma cells and inhibits the growth of ectopic tumor. Investigational new drugs 42 (4) (2024)
Randeep Sangha, Rahima Jamal, Jennifer Spratlin, John Kuruvilla, Laurie H Sehn, Erwan Beauchamp, Michael Weickert, Luc G Berthiaume, John R Mackey
A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas. Investigational new drugs 42 (4) (2024)
Yanqi Zhong, Heng Zhang, Peng Wang, Jing Zhao, Yuxi Ge, Zongqiong Sun, Zi Wang, Jie Li, Shudong Hu
Auger emitter in combination with Olaparib suppresses tumor growth via promoting antitumor immune responses in pancreatic cancer. Investigational new drugs 42 (4) (2024)
Sujinna Lekmeechai, Kristian Pietras, Oskar Axelsson
177 Lu-SN201 nanoparticle shows superior anti-tumor efficacy over conventional cancer drugs in 4T1 orthotopic model. Investigational new drugs 42 (4) (2024)
Noboru Yamamoto, Yasutoshi Kuboki, Kenichi Harano, Takafumi Koyama, Shunsuke Kondo, Akiko Hagiwara, Noriko Suzuki, Ei Fujikawa, Kiichiro Toyoizumi, Mayumi Mukai, Toshihiko Doi
A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors. Investigational new drugs 42 (4) (2024)
Nicholas G Kounis, Virginia Mplani
Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis: hypersensitivity myocarditis, or something else. Investigational new drugs 42 (4) (2024)
Kai Fan, Yueyuan Wang, Jiangyujing Bian, Yewen Sun, Jiaqi Dou, Jie Pan, Yunli Yu
Study on the effects of rapamycin and the mTORC1/2 dual inhibitor OSI-027 on the metabolism of colon cancer cells based on UPLC-MS/MS metabolomics. Investigational new drugs 42 (4) (2024)
John R Cashman, Emily A Cashman
Effect of PAWI-2 on pancreatic cancer stem cell tumors. Investigational new drugs 42 (4) (2024)
Noboru Yamamoto, Yasutoshi Kuboki, Kenichi Harano, Takafumi Koyama, Shunsuke Kondo, Akiko Hagiwara, Noriko Suzuki, Ei Fujikawa, Kiichiro Toyoizumi, Mayumi Mukai, Toshihiko Doi
A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors. Investigational new drugs 42 (4) (2024)
Kai Fan, Yueyuan Wang, Jiangyujing Bian, Yewen Sun, Jiaqi Dou, Jie Pan, Yunli Yu
Study on the effects of rapamycin and the mTORC1/2 dual inhibitor OSI-027 on the metabolism of colon cancer cells based on UPLC-MS/MS metabolomics. Investigational new drugs 42 (4) (2024)
Dongmei Ji, Weina Shen, Ting Li, Huan Wang, Jianling Bai, Junning Cao, Xichun Hu
Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study. Investigational new drugs 42 (4) (2024)
Randeep Sangha, Rahima Jamal, Jennifer Spratlin, John Kuruvilla, Laurie H Sehn, Erwan Beauchamp, Michael Weickert, Luc G Berthiaume, John R Mackey
A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas. Investigational new drugs 42 (4) (2024)
Dongmei Ji, Weina Shen, Ting Li, Huan Wang, Jianling Bai, Junning Cao, Xichun Hu
Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study. Investigational new drugs 42 (4) (2024)
Kazufumi Kobayashi, Sadahisa Ogasawara, Ei Itobayashi, Tomomi Okubo, Norio Itokawa, Kazuyoshi Nakamura, Michihisa Moriguchi, Shunji Watanabe, Masafumi Ikeda, Hidekatsu Kuroda, Tomokazu Kawaoka, Atsushi Hiraoka, Yutaka Yasui, Teiji Kuzuya, Rui Sato, Hiroaki Kanzaki, Keisuke Koroki, Masanori Inoue, Masato Nakamura, Soichiro Kiyono, Naoya Kanogawa, Takayuki Kondo, Shingo Nakamoto, Yoshihito Ozawa, Kaoru Tsuchiya, Masanori Atsukawa, Hiroshi Aikata, Takeshi Aramaki, Shiro Oka, Naoki Morimoto, Masayuki Kurosaki, Yoshito Itoh, Namiki Izumi, Naoya Kato
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study). Investigational new drugs 42 (4) (2024)
Dongmei Ji, Weina Shen, Ting Li, Huan Wang, Jianling Bai, Junning Cao, Xichun Hu
Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study. Investigational new drugs 42 (4) (2024)
Michael J Hanley, Steven Zhang, Robert J Griffin, Sean Xiaochun Zhu, Robert J Fram, Jianchang Lin, Karthik Venkatakrishnan, Neeraj Gupta
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [ 14 C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Investigational new drugs 42 (4) (2024)
Sujinna Lekmeechai, Kristian Pietras, Oskar Axelsson
177 Lu-SN201 nanoparticle shows superior anti-tumor efficacy over conventional cancer drugs in 4T1 orthotopic model. Investigational new drugs 42 (4) (2024)
Michael J Hanley, Steven Zhang, Robert J Griffin, Sean Xiaochun Zhu, Robert J Fram, Jianchang Lin, Karthik Venkatakrishnan, Neeraj Gupta
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [ 14 C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Investigational new drugs 42 (4) (2024)